Aspirin: Difference between revisions

Revision as of 12:09, 24 January 2019

Aspirin is an AINE ^[1] A recommendation of AAs-clopidogrel to maintain the patency of the stent following coronary intervention. Clopidogrel is a P2Y12 inhibig platelet agent; the combination AAs Ticagrelor wasn´t better than clopidogrel+aspirin ^[2]

Kawasaki

Protocols recommend AAs and intravenous immunoglubin; hwever many cases have be shown to be refractory to this treatment ^[3]

Hutchinson Gliford Progeria

Low dosis Aspirin 2-3 mg/Kg body weight is recommended for prevention of cardiovascular and stroke complications ^[4]

Links

Level and variation on quality of care in China: a cross-sectional study for the acute myocardial infarction patients in tertiary hospitals in Beijing

↑ https://karmel.miraheze.org/wiki/PenaRC2/profilaxis_AAS
↑ https://www.mdpi.com/2077-0383/8/1/104/htm Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting]
↑ A case report of refractory kawasaki disease
↑ Hutchinson-Gilford Progeria Syndrome

Interwiki via Wikidata

[1] ttps://karmel.miraheze.org/wiki/PenaRC2/profilaxis_AAS

[2] ttps://www.mdpi.com/2077-0383/8/1/104/htm Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting]

[3] A case report of refractory kawasaki disease

[4] Hutchinson-Gilford Progeria Syndrome

[1]

[2]

[3]

[4]

Revision as of 12:07, 24 January 2019 (view source) Penarc (talk \| contribs) m (→‎Kawasaki) ← Older edit		Revision as of 12:09, 24 January 2019 (view source) Penarc (talk \| contribs) m (→‎Links) Newer edit →
Line 18:		Line 18:


	{{Wikidata\|Q}}		{{Wikidata\|Q18216}}

Aspirin: Difference between revisions

Revision as of 12:09, 24 January 2019

Kawasaki

Hutchinson Gliford Progeria

Links

Navigation menu

Search